Opioids: How to improve compliance and adherence

Pain Practice

Volumn 11, Issue 6, 2011, Pages 574-581

  Graziottin, Alessandra ^a   Gardner Nix, Jacqueline ^b   Stumpf, Maik ^c   Berliner, Michael N ^d  

^a Center of Gynecology   (Italy)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c JANSSEN CILAG GMBH   (Germany)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

Adherence; Chronic pain; Compliance; Long acting opioids

Indexed keywords

CONTINUS; HYDROMORPHONE; LONG ACTING DRUG; MORPHINE SULFATE; OPIATE; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ANALGESIA; ATTITUDE TO HEALTH; CHRONIC PAIN; CONSTIPATION; DEPRESSION; DOCTOR PATIENT RELATION; DRUG ABUSE; DRUG COST; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; FAMILY ATTITUDE; HEALTH; HUMAN; HYPERALGESIA; NAUSEA; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VOMITING;

EID: 80655144854     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00449.x     Document Type: Review

References (68)

1. Brennan F, Cousins MJ. Pain relief as a human right. Pain Clin Updates. 2004;XII. Available at: (accessed September 7, 2010).
2. Harstall C, Ospina M. How prevalent is chronic pain? Pain Clin Updates. 2003;XI. Available at: (accessed September 7, 2010).
3. Chronic Pain in America: Roadblocks to Relief, A Study Conducted by Roper Starch Worldwide for American Academy of Pain Medicine, American Pain Society and Janssen Pharmaceutica; 1999. Available at: (accessed September 7, 2010).
4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
5. World Health Organization (WHO). Adherence to Long-Term Therapies. Evidence for Action. Geneva, Switzerland; 2003. Available at: (accessed September 7, 2010).
6. Berliner MN, Stumpf M, Bornhövd K. Compliance-(k)ein thema in der schmerztherapie? MMW Fortschr Med Orig. 2008;1:S31-S35.
7. Graziottin A. Contraccezione ormonale. Le ragioni forti della compliance e dell'aderenza alla terapia. Roma: Il Pensiero Scientifico Editore; 2007. Available at: (accessed September 7, 2010).
8. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. The Cochrane Database Syst Rev. 2002, Issue 2. Art. No.: CD000011. DOI:.
9. Rich BA. Ethics of opioid analgesia for chronic noncancer pain. Pain Clin Updates. 2007;XV. Available at: (accessed September 7, 2010).
10. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
11. Stone GC. Patient compliance and the role of the expert. J Soc Issue. 1979;35:34-59.
12. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722-728.
13. Winkler A, Teuscher AU, Mueller B, Diem P. Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly. 2002;132:379-385.
14. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia. 1998;18:52-56.
15. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185-190.
16. Cheng JWM, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the sixth joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Pharmacotherapy. 2001;21:828-841.
17. Passik SD, Byers K, Kirsh KL. Empathy and the failure to treat pain. Palliat Support Care. 2007;5:167-172.
18. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Determinants of medication underuse and medication overuse in patients with chronic non-malignant pain: a multicenter study. Int J Nurs Stud. 2010;47:1408-1417.
19. Sale JE, Gignac M, Hawker G. How "bad" does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis. Arthritis Rheum. 2006;55:272-278.
20. Vallerand AH. The use of long-acting opioids in chronic pain management. Nurs Clin North Am. 2003;38:435-445.
21. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681-692.
22. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181-186.
23. Ferrell B, Wisdom C, Wenzl C, Brown J. Effects of controlled-release morphine on quality of life for cancer pain. Oncol Nurs Forum. 1989;16:521-526.
24. Gallagher RM, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. Pain Med. 2007;8:71-74.
25. Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. Clin J Pain. 2004;20:363-366.
26. Ackerman SJ, Mordin M, Reblando J, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003;9:223-231.
27. Malkin JD, Ackerman SJ, Schein J, et al. Cost and utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release in a california medicaid population. J Manag Care Pharm. 2002;8:132-140.
28. Burton AW, Fanciullo GJ, Beasley RD, Fisch JF. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007;8:189-198.
29. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287-299.
30. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag. 2006;2:137-146.
31. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006;28:943-952.
32. Bloodworth D. Issues in opioid management. Am J Phys Med Rehabil. 2005;84(3 suppl):S42-S55.
33. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005;6:21-28.
34. Watson CP, Watt-Watson JH, Chipman ML. Chronic noncancer pain and the long term utility of opioids. Pain Res Manag. 2004;9:19-24.
35. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage. 2003;26:1026-1048.
36. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, IL: American Pain Society; 2003.
37. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23:355-368.
38. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain; 2010. Available at: (accessed September 7, 2010).
39. Jovey RD, Ennis J, Gardner-Nix J, et al. Canadian Pain Society. Use of opioid analgesics for the treatment of chronic noncancer pain - a consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag. 2003;8(suppl A):3A-28A.
40. Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7:381-386.
41. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50:S205-S224.
42. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287-313.
43. American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
44. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7:671-681.
45. McNicol E. Opioid side effects. Pain Clin Updates. 2007;XV. Available at: (accessed September 7, 2010).
46. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10:479-491.
47. Clemens KE, Klaschik E. Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide. Ther Clin Risk Manag. 2010;6:77-82.
48. Rao SS, Go JT. Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging. 2010;5:163-171.
49. Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007;22:485-490.
50. Wallace LS, Keenum AJ, Roskos SE, McDaniel KS. Development and validation of a low-literacy opioid contract. J Pain. 2007;8:759-766.
51. Lin CC, Chou PL, Wu SL, Chang YC, Lai YL. Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer pain. Pain. 2006;122:271-281.
52. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. 2007;91:199-211.
53. Sinatra R. Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain. J Am Board Fam Med. 2006;19:165-177.
54. Mao J. Opioid-induced hyperalgesia. Pain Clin Updates. 2008;XVI. Available at: (accessed September 7, 2010).
55. Adams EH, Breiner S, Cicero TJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006;31:465-476.
56. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.
57. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008; 11(2 suppl):S181-S200.
58. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs. 2003;63:17-32.
59. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician. 2006;52:1081-1087.
60. Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol. 2007;26:1-9.
61. ® [Package Insert]. San Diego, CA: Ligand Pharmaceuticals Inc.; 2005.
62. ® [Package Insert]. Piscataway, NJ: Alpharma Pharmaceuticals LLC; 2008.
63. ® [Package Insert]. Cambridge, UK: Napp Pharmaceuticals Ltd.; 2009.
64. Jurnista™ Monograph. Toronto, ON: Janssen Inc.; 2010.
65. ® Monograph. Pickering, ON: Purdue Pharma; 2008.
66. ® SR [Package Insert]. Cambridge, UK: Napp Pharmaceuticals Ltd.; 2009.
67. ® ER [Package Insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2008.
68. ® Monograph. Pickering, ON: Purdue Pharma; 2009.